Preparations of calcipotriol are indicated for the treatment of moderate plaque psoriasis. Other therapeutic uses include congenital ichthyosis, hereditary epidermolytic palmoplantar keratoderma, pityriasis rubra, and pustular psoriasis.

The effectiveness of topical calcipotriol in the treatment of psoriasis results mainly from inhibition of epidermal proliferation and stimulation of differentiation of epidermal cells. Although calcipotriol appears to exert a significantly lesser effect on calcium metabolism than does calcitriol, some investigators feel there is no advantage in using topical calcipotriol over topical calcitriol in psoriasis patients.

Vitamin D toxicity. Hypercalcemia. Do not apply to the face. Hypersensitivity to calcipotriol or any ingredient

C

Infant risk can not be ruled out.

Transient, rapidly reversible elevation of serum calcium has occurred with the use of calcipotriol. The use of calcipotriol may cause burning, stinging, erythema, and a facial dermatitis.

Topical application BID, discontinued if serum calcium is above normal range. Do not exceed maximum dose of 100-g ointment per week. Children: Maximum dose: age over 12 yrs 75 g/week, 6-12 yrs 50 g/week, under 6 yrs no maximum safe dose known, but 25 g/week is consider appropriate. Pregnant women: started with QD combined with a group III corticosteroid also QD topically. The maximum dose is 25 g/week.